Lapatinib

For research use only.

Catalog No.S2111 Synonyms: GW-572016, GSK572016

328 publications

Lapatinib Chemical Structure

Molecular Weight(MW): 581.06

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 143 In stock
USD 110 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Lapatinib has been cited by 328 publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
Targets
ErbB2 [1]
(Cell-free assay)
EGFR [1]
(Cell-free assay)
ErbB4 [1]
(Cell-free assay)
9.2 nM 10.8 nM 367 nM
In vitro

Lapatinib weakly inhibits the activity of ErbB4 with IC50 of 367 nM, and displays >300-fold selectivity for EGFR and ErbB2 over other kinases such as c-Src, c-Raf, MEK, ERK, c-Fms, CDK1, CDK2, p38, Tie-2, and VEGFR2. Lapatinib significantly inhibits receptor autophosphorylation of EGFR and ErbB2 in a dose-dependent manner with IC50 of 170 nM and 80 nM, respectively in HN5 cells; as well as 210 nM and 60 nM, respectively in BT474 cells. Unlike OSI-774 and Iressa (ZD1839) which preferentially inhibit the growth of the EGFR-overexpressing cells, Lapatinib inhibits the growth of both EGFR- and ErbB2-overexpressing cells. Lapatinib displays higher inhibitory activity against EGFR- or ErbB2-overexpressing cells with IC50 of 0.09-0.21 μM, compared with cells expressing low levels of EGFR or ErbB2 with IC50 of 3-12 μM, and exhibits ~100-fold selectivity over the normal fibroblast cells. Lapatinib potently inhibits the outgrowth of EGFR-overexpressing HN5 and A-431 cells, as well as ErbB2-overexpressing BT474 and N87 cells, and significantly induces G1 arrest of HN5 cells and apoptosis of BT474 cells, which are associated with inhibition of AKT phosphorylation. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H1648 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfqVlZ4UUN3ME2wMlAzPTR2IN88US=> NUTUXIV5W0GQR1XS
HCC2218 M4LkXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3OdplKSzVyPUCuNFU{OjZizszN MWnTRW5ITVJ?
OCUB-M MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjOWnVKSzVyPUCuNFU4PCEQvF2= NYnr[nI5W0GQR1XS
ECC12 Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DvNWlEPTB;MD6wPVI{OSEQvF2= NUHVUVRIW0GQR1XS
DSH1 NGnSPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvY[HBNUUN3ME2wMlA6Ozl4IN88US=> NULF[W5UW0GQR1XS
BT-474 NHKxXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwMkGzNVUh|ryP NHjCXHZUSU6JRWK=
BB30-HNC M2XmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMkS2OVQh|ryP MoTqV2FPT0WU
EKVX MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwNES4O|Qh|ryP MVTTRW5ITVJ?
TE-12 MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzEPGFKSzVyPUCuOFkxPTdizszN NEXDUm9USU6JRWK=
A388 MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInwNWFKSzVyPUCuO|IzPThizszN MoTmV2FPT0WU
TE-9 MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT6TWM2OD1yLke0OFU{KM7:TR?= NFP3UY9USU6JRWK=
LB2241-RCC M1ztTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TSSmlEPTB;MT6xOVQxOyEQvF2= Mkn0V2FPT0WU
LB996-RCC Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn61TWM2OD1zLkO2NlI5KM7:TR?= MVPTRW5ITVJ?
LC-1F MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[1bpRKSzVyPUGuN|gzPDRizszN NUHrTndEW0GQR1XS
TE-6 NEHUNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3oTWM2OD1zLkW1NlAyKM7:TR?= M4m0bnNCVkeHUh?=
A253 NXXjd5pDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nXdWlEPTB;MT65O|M{PSEQvF2= M{e0d3NCVkeHUh?=
OS-RC-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M160ZmlEPTB;MT65PVE6QSEQvF2= M3jtUnNCVkeHUh?=
TE-1 NFXFXZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHP6WZVKSzVyPUKuNFQ5OyEQvF2= MmiwV2FPT0WU
RL95-2 NWjxWFU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfaUmpKSzVyPUOuNVU3PyEQvF2= M4fyU3NCVkeHUh?=
LS-513 M1vEdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHwTWM2OD1|LkSwNFQyKM7:TR?= NUnUbXRkW0GQR1XS
DJM-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTNwNE[5O|Uh|ryP NIXpPGtUSU6JRWK=
NMC-G1 NV7nPGNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{K0S2lEPTB;Mz61OFUxOSEQvF2= MlnqV2FPT0WU
TE-10 NUHlfFIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTNwNUWzOVYh|ryP MnS4V2FPT0WU
TE-5 NGLMeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDRTINKSzVyPUSuNFM4OyEQvF2= NGKxNmxUSU6JRWK=
TK10 M2X6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrqfIxKSzVyPUSuNVY2OjJizszN NXPZOJhrW0GQR1XS
UACC-812 NXH1T5FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\yTWM2OD12LkW2NVU{KM7:TR?= NETnZ3lUSU6JRWK=
SW962 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nXSGlEPTB;NT6wNlE2QSEQvF2= MXzTRW5ITVJ?
SW954 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\4XmlEPTB;NT6zPVI1PSEQvF2= MXTTRW5ITVJ?
COLO-668 M3\U[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;ocHJKSzVyPUWuO|I3PjdizszN NEHXTJJUSU6JRWK=
LB1047-RCC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;ETWM2OD13LkiwNFQ3KM7:TR?= NGXFcYNUSU6JRWK=
NB5 MkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXFTWM2OD14LkKxNFAyKM7:TR?= MlnsV2FPT0WU
NTERA-S-cl-D1 M4XhVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEixUZdKSzVyPU[uNlY2PjFizszN NYHPSmlnW0GQR1XS
IST-MEL1 NV\QdI5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIq0VJNKSzVyPU[uOFM3QTRizszN NEe5PJNUSU6JRWK=
GI-1 MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jVU2lEPTB;Nj61NVY5OiEQvF2= M{D4eXNCVkeHUh?=
TGBC1TKB NVT0UYZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTITWM2OD15LkC3NVg{KM7:TR?= MoXFV2FPT0WU
GT3TKB MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYCzZ|Q{UUN3ME23MlIzPzR2IN88US=> M2Toc3NCVkeHUh?=
EVSA-T M3XlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnOVVRKSzVyPUeuOFI5OTFizszN MWTTRW5ITVJ?
D-502MG M2\XSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jhdmlEPTB;Nz60PFg6PCEQvF2= MljXV2FPT0WU
TE-8 NVyyWVR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTdwN{[xOVkh|ryP MXrTRW5ITVJ?
OVCAR-4 MnS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7hcXZDUUN3ME25MlEyPjd3IN88US=> NXHzc4JOW0GQR1XS
D-336MG MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[3T5hRUUN3ME25MlQ4Ozl3IN88US=> MXzTRW5ITVJ?
GCIY MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjXc2lKSzVyPUmuOVc1OiEQvF2= MVLTRW5ITVJ?
KS-1 Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTlwNk[yPFch|ryP NEPqNJZUSU6JRWK=
HCC2998 NWHrXpFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTlwOU[zNFch|ryP M4DuR3NCVkeHUh?=
D-247MG NHHuSYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTlwOUiyPVEh|ryP NE[1XHhUSU6JRWK=
TE-15 NGHZRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjiUlA2UUN3ME2xNE4zPDVizszN MXzTRW5ITVJ?
IST-MES1 M1zDR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;yTWM2OD1zMD6yOVY2KM7:TR?= NYG1RlFiW0GQR1XS
ETK-1 NGH6dIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFyLk[yN{DPxE1? M37uRnNCVkeHUh?=
RCC10RGB MnnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFyLkm2NUDPxE1? MmfiV2FPT0WU
KNS-42 NYPnU3htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XBd2lEPTB;MUGuO|I2PSEQvF2= NX\wcZVtW0GQR1XS
LB771-HNC NGTxRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTF{LkG3NVIh|ryP MVfTRW5ITVJ?
SR MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\DTItSUUN3ME2xNk4zODZ2IN88US=> NGL5em1USU6JRWK=
NCI-H1355 MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF{Lki5PFUh|ryP NGD1b3FUSU6JRWK=
ES6 Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrNWI5ZUUN3ME2xN{4xPzhizszN M{XVWnNCVkeHUh?=
SK-NEP-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTF|LkK1O|ch|ryP NU\uemZxW0GQR1XS
D-392MG NX7wUYhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofhTWM2OD1zMz62OFI5KM7:TR?= MoPBV2FPT0WU
NB7 NW[2fFFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzvXZBKSzVyPUG0MlI{PzRizszN MV;TRW5ITVJ?
SK-LMS-1 NWW2fYFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF2LkWxOFUh|ryP NXfJcWZ3W0GQR1XS
SK-UT-1 M3nL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7YOlVKSzVyPUG0Mlc5QDlizszN MYTTRW5ITVJ?
CA46 NXX3U4U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3eycGlEPTB;MUWuNFU5PiEQvF2= Mnm1V2FPT0WU
IST-SL2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF3LkG5NFEh|ryP M2f0SHNCVkeHUh?=
BC-1 M37PW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3ITWM2OD1zNT6zN|E1KM7:TR?= NFG2cpRUSU6JRWK=
LS-123 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml64TWM2OD1zNT64NVc{KM7:TR?= MlvJV2FPT0WU
Ramos-2G6-4C10 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTF4LkC5NlQh|ryP MkGxV2FPT0WU
MZ1-PC MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvFPIxIUUN3ME2xOk44OzF|IN88US=> MV;TRW5ITVJ?
LB647-SCLC M122RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnnXYFMUUN3ME2xOk46Ozd{IN88US=> MlzSV2FPT0WU
NCI-H1694 M2\Bb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPXTWM2OD1zNz6xOVI6KM7:TR?= NIrlSnJUSU6JRWK=
NCI-H322M NGn5Z2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP3TWtKSzVyPUG3MlQ{PjZizszN NF;GWmhUSU6JRWK=
ES7 NWK5fVBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfMcZBiUUN3ME2xPE4{QTF2IN88US=> NXKzcZk5W0GQR1XS
LC-2-ad M3;QcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\hNFBKSzVyPUG4MlQ{QDZizszN Mo\oV2FPT0WU
SF268 M3vXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XhRWlEPTB;MUiuO|QxQSEQvF2= M3P6bXNCVkeHUh?=
RPMI-8402 MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzlPXpyUUN3ME2xPU4xPzR{IN88US=> MkK0V2FPT0WU
HCE-T MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHSzdpVKSzVyPUKwMlI{PDRizszN NF\IW2tUSU6JRWK=
A101D NYjwbYtST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnziTWM2OD1{MD64OVg4KM7:TR?= NUTyU4xVW0GQR1XS
MRK-nu-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzPUHJKSzVyPUKwMlkyOyEQvF2= Mm[yV2FPT0WU
LXF-289 M{fZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DocGlEPTB;MkGuNFM5KM7:TR?= M3rzUnNCVkeHUh?=
NALM-6 NXKxdYk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7EPI1KSzVyPUKxMlE6PjdizszN MUjTRW5ITVJ?
DOHH-2 MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJzLkS4NVMh|ryP MXjTRW5ITVJ?
EW-16 NV\lc48xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\nOplKSzVyPUKyMlE1ODJizszN M4ThWXNCVkeHUh?=
A4-Fuk M{[1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jYOmlEPTB;MkKuNlE1QSEQvF2= MWfTRW5ITVJ?
HD-MY-Z Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjqPJBZUUN3ME2yNk4{QTZ3IN88US=> M3frb3NCVkeHUh?=
SKM-1 NUjoU4VWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHNbnVKSzVyPUKyMlc{PTFizszN NUDUZY9EW0GQR1XS
DMS-153 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWGwOJp3UUN3ME2yN{41OjB2IN88US=> M1[5ZXNCVkeHUh?=
LB373-MEL-D M3rPfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJ|LkW0OVIh|ryP MnrnV2FPT0WU
LP-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3FS3l4UUN3ME2yN{45ODl5IN88US=> MUnTRW5ITVJ?
GI-ME-N M3fKOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTXS4tKSzVyPUK0MlI6OiEQvF2= M2Wxb3NCVkeHUh?=
MPP-89 M{fNWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJ3LkKwN|Yh|ryP M13WSHNCVkeHUh?=
U-698-M NXvJVoFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjtbIV5UUN3ME2yOU4zPTB|IN88US=> NYDPS5J[W0GQR1XS
HC-1 NWLXSIR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXuzeJJSUUN3ME2yOU43PDF6IN88US=> NXr2dI9NW0GQR1XS
HCC2157 M1n0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLkfG1KSzVyPUK1MlY4OyEQvF2= NITjVHFUSU6JRWK=
MOLT-4 NV7SbXpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf6WGtKSzVyPUK2MlI4OyEQvF2= MXrTRW5ITVJ?
LS-411N MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLzVnJKSzVyPUK2MlM{PjlizszN MWXTRW5ITVJ?
Becker M{PsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH2SoFyUUN3ME2yOk42OThzIN88US=> MlPrV2FPT0WU
NCI-H23 Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XpZWlEPTB;Mk[uO|U4PSEQvF2= Mn7RV2FPT0WU
IST-SL1 MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJ5LkO4Olch|ryP NVHGfZJVW0GQR1XS
MZ2-MEL NGPM[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL6d5Z6UUN3ME2yO{41PTZ4IN88US=> M{n2bnNCVkeHUh?=
RKO NEPJfVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH20XJJKSzVyPUK4MlE1PDZizszN M{HBcnNCVkeHUh?=
TE-441-T NUHyfmZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LWcGlEPTB;MkiuO|g6KM7:TR?= M3zaN3NCVkeHUh?=
EW-24 M3fGNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTJ7LkGyOVkh|ryP M3PJe3NCVkeHUh?=
no-10 M{Hs[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJ7LkG2N|Eh|ryP NXT0OpRYW0GQR1XS
D-542MG NV[5T5FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\yfpR3UUN3ME2yPU46OjJzIN88US=> NG\z[4JUSU6JRWK=
ST486 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TqdmlEPTB;M{CuOlQ2OSEQvF2= MnTMV2FPT0WU
KURAMOCHI MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17LbGlEPTB;M{CuPFA2PyEQvF2= MoPPV2FPT0WU
ES8 MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG4TWM2OD1|MT61PVczKM7:TR?= NFrFNndUSU6JRWK=
BL-41 NGnM[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4iwfWlEPTB;M{KuNVA2PCEQvF2= M3n2XnNCVkeHUh?=
NB6 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTN{LkO4OVUh|ryP MV7TRW5ITVJ?
NCI-H1304 NEfUXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfhTJZKSzVyPUOyMlQ6PjdizszN M4TqTHNCVkeHUh?=
MS-1 M{fCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkO1TWM2OD1|Mj63O|UyKM7:TR?= NUHzOYV1W0GQR1XS
MFH-ino MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\ZOWlEPTB;M{SuN|IzPCEQvF2= MlzHV2FPT0WU
NOS-1 NF65XoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfFfpJKSzVyPUO0MlY4PDhizszN NHrOfpVUSU6JRWK=
HUTU-80 NUDKcI9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTN3LkO2Olch|ryP MUXTRW5ITVJ?
EB2 NH;XdJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDjTWM2OD1|Nj62NVg6KM7:TR?= MWPTRW5ITVJ?
L-540 NXnITFUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPwTWM2OD1|Nz6yN|A5KM7:TR?= NETVZY5USU6JRWK=
NCI-H747 NHn5OFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX4e4VwUUN3ME2zPE45QDR4IN88US=> NVvySVZ[W0GQR1XS
NCI-H446 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXVTWM2OD1|OT65OlUyKM7:TR?= MmDlV2FPT0WU
MOLT-16 NYLFO5VKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmToTWM2OD12Mj60NVUh|ryP NHjCXnBUSU6JRWK=
BC-3 MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moj6TWM2OD12NT60PFk3KM7:TR?= MnfFV2FPT0WU
SJSA-1 NFjGcYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfhTWM2OD12NT61OFc1KM7:TR?= NEHZV45USU6JRWK=
BB65-RCC M3XwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrFTWM2OD12NT62OlYh|ryP M1X2WHNCVkeHUh?=
SNB75 NFLvWHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTR4LkCxPEDPxE1? MXLTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
ERBB2 / pERBB2 / p53 / Mdm2 / MdmX / pERK / Hsp70 ; 

PubMed: 29799521     


Downregulation of HSF1, mutp53, and Mdm2 in lapatinib-sensitive parental BT474, but not in lapatinib-resistant BT474R cells, treated with indicated lapatinib concentrations for 24 h.

pEGFR / EGFR / pAkt / Akt / pmTOR / mTOR / PARP / c-PARP ; 

PubMed: 28938602     


SKBR3 and 78617 cells were treated with lapatinib as in panel A, then the expression of phospho-ErbB2 (Tyr1221/1222), ErbB2, phospho-EGFR (Tyr1068), EGFR, phospho-Akt (Ser473), Akt, phospho-Erk1/2 (Thr202/Tyr204), Erk2, phospho-mTOR (Ser2448), and mTOR were analyzed using Western blotting. 

p-HER2 / HER2 / p-HER3 / HER3 / p-S6 / S6 / p-4EBP1; 

PubMed: 22853430     


A panel of HER2-amplified breast cancer cells were treated with 200nM lapatinib for up to 72 hours to detect the initial downregulation and subsequent upregulation of HER2-HER3 and downstream signaling. Immunoblots were performed using the indicated antibodies.

29799521 28938602 22853430
Immunofluorescence
LC3 ; 

PubMed: 26637440     


SKBR3 GFP-LC3 cells were cultured for 6 days and UACC893 GFP-LC3 cells were cultured for 7 days with 5 μM EZN3046 or EZN4150 .

Vimentin / E-cadherin; 

PubMed: 28243326     


Cells treated with lapatinib (5µM) increased the expression of E-cadherin and inhibited the expression of Vimentin by immunofluorescence. (Magnification: 1000×).

26637440 28243326
Growth inhibition assay
Cell viability (OE19); 

PubMed: 25350844     


Dose-response curves from escalated dose of lapatinib in the presence of 1 µM concentration of saracatinib. The calculated values of IC50 for lapatinib were following; 207.3 nM and 145 nM, respectively, after lapatinib alone and in the presence of saracatinib for parental OE19; >1,000 nM after lapatinib alone for LR2A and LR2B; 91.66 nM and 224.0 nM in the presence of saracatinib in LR2A and LR2B, respectively. Values were presented as relative cellular viability relative to vehicle-treated controls with the mean ± S.E. of quadruplicate from a representative experiment. The p values calculated by two-way ANOVA were <0.0001 comparing lapatinib alone with lapatinib plus saracatinib both in the LR2A and LR2B.

Cell viability (A431 cells); 

PubMed: 28243326     


The MTT assay was performed on the viability of A431 cells by lapatinib at different concentrations (0.1-50μM) and IC50 value was analyzed as indicated on the plot (t-test).

25350844 28243326
In vivo Oral administration of Lapatinib (~100 mg/kg) twice daily significantly inhibits the growth of BT474 and HN5 xenografts in a dose-dependent manner. [1]

Protocol

Kinase Assay:[1]
- Collapse

In vitro kinase assays:

The IC50 values for inhibition of enzyme activity are generated by measuring inhibition of phosphorylation of a peptide substrate. The intracellular kinase domains of EGFR and ErbB2 are purified from a baculovirus expression system. EGFR and ErbB2 reactions are performed in 96-well polystyrene round-bottomed plates in a final volume of 45 μL. Reaction mixtures contain 50 mM 4-morpholinepropanesulfonic acid (pH 7.5), 2 mM MnCl2, 10 μM ATP, 1 μCi of [γ33P] ATP/reaction, 50 μM Peptide A [Biotin-(amino hexonoic acid)-EEEEYFELVAKKK-CONH2], 1 mM dithiothreitol, and 1 μL of DMSO containing serial dilutions of Lapatinib beginning at 10 μM. The reaction is initiated by adding the indicated purified type-1 receptor intracellular domain. The amount of enzyme added is 1 pmol/reaction (20 nM). Reactions are terminated after 10 minutes at 23°C by adding 45 μL of 0.5% phosphoric acid in water. The terminated reaction mix (75 μL) is transferred to phosphocellulose filter plates. The plates are filtered and washed three times with 200 μL of 0.5% phosphoric acid. Scintillation cocktail (50 μL) is added to each well, and the assay is quantified by counting in a Packard Topcount. IC50 values are generated from 10-point dose-response curves.
Cell Research:[1]
- Collapse
  • Cell lines: HFF, MCF-7, T47D, A-431, HN5, BT474, N87, CaLu-3, HB4a, and HB4a c5.2 cells
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 72 hours
  • Method: Cells are exposed to various concentrations of Lapatinib for 72 hours. Relative cell number is estimated using methylene blue staining. The absorbance at 620 nm is read in a Spectra microplate reader. Cell death and cell cycle analysis are assessed by propidium iodide staining and antibody detection of incorporated BrdUrd and staining with propidium iodide.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: CD-1 nude female mice implanted s.c. with HN5 cells, and C.B-17 SCID female mice implanted s.c. with BT474 cells
  • Dosages: ~100 mg/kg
  • Administration: Orally twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (172.09 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.06
Formula

C29H26ClFN4O4S

CAS No. 231277-92-2
Storage powder
in solvent
Synonyms GW-572016, GSK572016
Smiles C[S](=O)(=O)CCNCC1=CC=C(O1)C2=CC=C3N=CN=C(NC4=CC=C(OCC5=CC=CC(=C5)F)C(=C4)Cl)C3=C2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03075995 Unknown status Other: hight-fat breakfast Breast Cancer Sun Yat-sen University April 12 2017 Not Applicable
NCT02338245 Completed Drug: ASLAN001|Drug: Lapatinib|Drug: Capecitabine Metastatic Breast Cancer Aslan Pharmaceuticals December 29 2014 Phase 2
NCT02294786 Terminated Drug: Lapatinib|Drug: Capecitabine|Drug: Octreotide Cancer Novartis Pharmaceuticals|Novartis December 17 2014 Phase 2
NCT02213042 Completed Drug: Lapatinib|Biological: Trastuzumab Neoplasms Breast Novartis Pharmaceuticals|Novartis October 24 2014 Phase 2
NCT01782651 Completed Drug: Lapatinib plus capecitabine Neoplasms Breast GlaxoSmithKline August 2014 --
NCT02158507 Active not recruiting Drug: Combination of Veliparib + Lapatinib Metastatic Triple Negative Breast Cancer University of Alabama at Birmingham|Scariot Foundation|GlaxoSmithKline|AbbVie July 2014 Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    If I want to use this compound(S2111, Lapatinib) in tumor-bearing mice via injection, how could I prepare the solution?

  • Answer:

    For I.P. administration, the compound solution should be clear solution. S2111 Lapatinib can be dissolved in 2% DMSO/30% PEG 300/5% Tween 80/ddH2O at 10 mg/ml for clear solution.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products

Tags: buy Lapatinib | Lapatinib supplier | purchase Lapatinib | Lapatinib cost | Lapatinib manufacturer | order Lapatinib | Lapatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID